SEELOS THERAPEUTICS INC (SEEL)
US81577F2083 - Common Stock
SEEL Stock Earnings: Seelos Therapeutics Beats EPS, Beats Revenue for Q1 2024
SEEL stock results show that Seelos Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!
SEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023
SEEL stock results show that Seelos Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
SEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Seelos Therapeutics (NASDAQ:SEEL) just reported results for the fourth quarter ...
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...
Psychedelic stocks gain after FDA priority review for MDMA therapy (NYSE:CYBN)
The FDA priority review for an MDMA-linked therapy leads to a surge in shares of psychedelic medicine companies such as Mind Medicine (MNMD). Read more here.
Seelos Therapeutics announces equity and warrants offering of $4M (NASDAQ:SEEL)
Seelos Therapeutics announces a direct offering of common shares and warrants, with proceeds to be used for corporate purposes and product development.
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies...
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
/PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies...
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024.
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...
Seelos Therapeutics files for $250M mixed shelf (NASDAQ:SEEL)
Seelos Therapeutics files prospectus for a shelf offering of up to $250M.
Seelos Therapeutics says CFO Golembiewski buys 83K shares in co (NASDAQ:SEEL)
Seelos Therapeutics CFO, Michael Golembiewski, purchases 83K shares at $1.20 each.